Business
Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Announced positive update in third quarter from SELECT-HD trial in HD; single doses of WVE-003 appeared generally safe and well-tolerated and suggested
About this update from Wave Life Sciences Ltd.
[{"type":"text","content":"Announced positive update in third quarter from SELECT-HD trial in HD; single doses of WVE-003 appeared generally safe and well-tolerated and suggested allele-selective reduction of mHTT protein in CSF Multidosing underway in Phase 1b/2a trial of WVE-N531 in boys with DMD amenable to exon 53 skipping; muscle biopsy data from initial cohort on track for 4Q 2022 Selected WVE-006 (Wave’s first RNA editing candidate) as development candidate for AATD with CTA submissions expected in 2023 Preclinical data presentations at OTS and ESGCT meetings highlighted potential of PRISM platform to develop potent and durable siRNA compounds and unlock new biology with AIMers Wave to host investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. “In the third quarter, we continued to deliver on our key milestones for 2022, including announcing a positive update from our Huntington’s disease trial and selecting our first-in-class RNA editing candidate for alpha-1 antitrypsin deficiency,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. “Clinical data emerging from our pipeline supports the translational potential of our unique PRISM platform and we look forward to sharing a third data update this quarter with the first muscle biopsy data from our Phase 1b/2a clinical trial of WVE-N531 for Duchenne muscular dystrophy. Additionally, we believe that our RNA editing capability using endogenous ADAR enzymes provides a unique opportunity for Wave and we are well-positioned to be leaders in the editing field. We are working toward bringing RNA editing to the clinic and are on track to submit clinical trial applications for our alpha-1 antitrypsin deficiency program in 2023.” Recent Pipeline and Business Highlights SELECT-HD clinical trial for WVE-003 in Huntington’s disease (HD) continues to advance; only allele-selective clinical program designed to reduce mutant HTT and spare healthy HTT WVE-003 (PN-modified allele-selective silencing oligonucleotide) for HD is being evaluated in th...